Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
Analysis
Bristol-Myers posts better-than-expected results, Opdivo growth slows
NEW YORK - U.S. drugmaker Bristol-Myers Squibb Co reported higher-than-expected third-quarter profit on Thursday, helped by strong sales of blood thinner Eliquis, even as growth of its blockbuster cancer treatment Opdivo slowed.
More commentaries
Stock Pick
Merck and Company : Leader in oncology, modest valuation
With $46 billion in expected revenue this year, the American company Merck ranks sixth among the world's major pharmaceutical groups, behind J&J .
More Recommendations
Stock Trading Strategies
MERCK AND COMPANY - 10/29
No turn-around in sight
BUY
More Stock Trading Analysis
Upcoming event on MERCK AND COMPANY